All Dave Ross articles
-
News
CSL opens $1bn Australian vaccine and antivenom manufacturing facility
The Melbourne site adds Australia to a select group of nations with advanced cell-based influenza vaccine capabilities.
The Melbourne site adds Australia to a select group of nations with advanced cell-based influenza vaccine capabilities.